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Nebulised salbutamol administered during sputum induction
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Background: Inhalation of hypertonic or even isotonic saline during sputum induction may cause
bronchospasm in susceptible patients with asthma, despite premedication with 400 mg inhaled salbutamol
delivered by pressurised metered dose inhaler (pMDI). The bronchoprotection afforded by additional
inhaled salbutamol administered through the ultrasonic nebuliser during sputum induction was
investigated.
Methods: Twenty patients with moderate to severe asthma underwent sputum induction by inhaling saline
4.5% (or 0.9% if post-bronchodilation forced expiratory volume in 1 second (FEV1) ,65% predicted) for
10 minutes according to two protocols given 1 week apart in random order. At visit A the patients
received 400 mg salbutamol administered through a pMDI + spacer 20 minutes before induction while at
visit B the premedication was supplemented by 1500 mg nebulised salbutamol inhaled throughout the
induction procedure. Both the investigator and the patients were blind to the nebulised solution used. FEV1
was recorded during sputum induction at 1, 3, 5, and 10 minutes. Sputum cell counts and histamine,
tryptase and albumin levels in the supernatants were determined.
Results: The mean (SE) maximal reduction in FEV1 over the 10 minute period of sputum induction was
11.7 (2.8)% at visit A, which was significantly greater than at visit B (2.6 (1.2)%; mean difference 9% (95%
CI 2.7 to 15.4), p,0.01). Total and differential sputum cell counts as well as albumin, tryptase, and
histamine levels did not differ between the two visits.
Conclusion: The addition of inhaled salbutamol through an ultrasonic nebuliser markedly improves
bronchoprotection against saline induced bronchoconstriction in patients with moderate to severe asthma
undergoing sputum induction without affecting cell counts and inflammatory markers.
S
ince the first description of sputum induction by Pin et al
in 1992,1 the technique has been widely used in asthma
research. Although several studies have reported on the
methodology of sputum induction,2 some outstanding issues
with respect to the safety of the procedure remain. Inhalation
of hypertonic saline carries the risk of severe bronchocon-
striction in patients with bronchial hyperresponsiveness,3 and
hypertonic saline challenge is a recognised indirect challenge
to assess bronchial hyperresponsiveness in asthma.4 This has
led to the recommendation of using inhaled salbutamol 200–
400 mg before sputum induction in patients with asthma
unless measurement of bronchial responsiveness to saline is
an outcome of the study.5 In most studies inhaled salbutamol
has been delivered by pressurised metered dose inhaler
(pMDI), some authors combining the pMDI with a spacer to
improve lung deposition. Despite this type of premedication,
some asthmatic patients still experience breakthrough
bronchoconstriction. One way to reduce the risk of broncho-
constriction is to induce sputum by inhalation of isotonic
rather than hypertonic saline, as advocated by Pizzichini et al
for severe asthmatic exacerbations.6 However, even isotonic
saline may be sufficiently irritating to the airways to trigger
bronchospasm in asthmatic patients with very reactive
airways. The dose of salbutamol and the optimal way to
deliver it remains an issue for the safety of sputum
induction.5
We hypothesised that delivering salbutamol via ultrasonic
nebuliser together with isotonic or hypertonic saline may
provide better bronchoprotection than inhaled salbutamol
pMDI 400 mg alone administered through a Volumatic
chamber. We have assessed 20 patients with moderate to
severe asthma and compared the falls in forced expiratory
volume in 1 second (FEV1) that occurred during sputum
induction when subjects were premedicated with either
salbutamol pMDI (400 mg) or salbutamol pMDI (400 mg) +
nebulised salbutamol delivered throughout the induction
procedure. To ensure that nebulised salbutamol does not
affect the key indicators in the sputum we compared the two
induction procedures with respect to sputum cell counts and
several biochemical markers—albumin as an indicator of
plasma exudation and tryptase and histamine as markers of
mast cell activation—two activities that may theoretically be




Twenty patients with moderate to severe asthma diagnosed
according to ATS criteria8 were recruited from outpatient
clinics. Three had been admitted to hospital and five others
had received a course of systemic corticosteroids for a severe
asthma exacerbation during the previous year. The demo-
graphic and functional characteristics of the subjects are
shown in table 1.
Sixteen subjects received regular treatment with inhaled
corticosteroids, 11 of whom were also receiving inhaled long
acting b2 agonists. Two subjects were also on oral cortico-
steroids with a daily dose of 16 and 32 mg methylpredniso-
lone, respectively. Maintenance treatment was kept constant
over the 4 weeks preceding the study (table 2). The protocol
was approved by the local ethical committee and volunteers
gave their written informed consent.
Study design
This was a randomised crossover study. There was a run in
period during which subjects recorded their daily consump-
tion of relief bronchodilators into diary cards. Subjects were
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randomised to receive either inhaled salbutamol 400 mg
administered through pMDI and Volumatic (Glaxo Smith
Kline, UK) 20 minutes before sputum induction (visit A) or
the same regimen + additional nebulised salbutamol 1571 mg
during the sputum induction procedure (visit B). Both the
asthmatic subjects and the laboratory function technician
who performed sputum induction and spirometric tests were
blind to the inhaled solution used. The two sputum
inductions were separated by a period of 1 week and were
performed at the same time of the day (¡2 hours). There
was no change in the maintenance treatment between
inductions and subjects were allowed to take their usual
maintenance drugs (including long acting b2 agonists) on the
morning of the induction. Importantly, the mean consump-
tion of short acting bronchodilator during the preceding week
and the baseline lung function values before sputum
induction were similar between visits A and B (table 2).
FEV1 was measured as the best of three flow-volume
curves using an electronic spirometer (Spirobank, MIR,
Rome, Italy) before and 15 minutes after 400 mg inhaled salbu-
tamol, the latter value being considered as the baseline value.
Sputum induction was started with either hypertonic or
isotonic saline according to post-bronchodilator FEV1.
Patients with an FEV1 >65% predicted inhaled 4.5% saline
while those with FEV1 ,65% predicted were given 0.9%
saline instead. Two patients had a post- bronchodilator FEV1
slightly less than 65% predicted at visit A (62% and 64%
predicted, respectively) but more than 65% at visit B (66%
and 67% predicted, respectively). As visit A was the first visit
for these two patients, they also inhaled isotonic saline at
their second visit (visit B) for consistency.
Sputum induction
Saline was inhaled through an ultrasonic nebuliser (Devilbiss
2000), the mean output of which was calculated to be
0.93 ml/min. The cup of the nebuliser was filled with 50 ml
hypertonic/isotonic saline to which was added 1.75 ml
salbutamol solution at 5 mg/ml. The dose of nebulised
salbutamol was dependent on the duration of sputum
induction and was calculated by multiplying the concentra-
tion of salbutamol in the cup of the nebuliser (169 mg/ml) by
the output of the nebuliser (0.93 ml/min) and the duration of
the induction. FEV1 was measured at 1, 3, 5, and 10 minutes
after starting inhalation. Inhalation of saline was stopped
after 10 minutes or when a fall in FEV1 of .20% from
baseline had occurred. After performing spirometric mea-
surements at 5 and 10 minutes the subjects were asked to
rinse their mouth with tap water and to cough up sputum
into a plastic container. For safety reasons, FEV1 was
measured 10 and 20 minutes after the end of the induction
in every patient. Two subjects who still had a fall in FEV1 of
.20% at this time received additional nebulised salbutamol
and ipratropium bromide and were kept under observation
until their FEV1 value had returned to within 5% of baseline.
Sputum processing
Samples were poured into a 50 ml polypropylene tube,
weighed, and diluted with a threefold weight of a phosphate
buffered saline (PBS) solution for homogenisation. The
samples were then rocked at room temperature for 20 min-
utes and centrifuged at 400 g for 10 minutes at 4 C˚. The
supernatant was stored at –80 C˚ until biochemical analyses
for albumin and histamine. The cellular phase was dispersed
in 1 ml PBS without Ca2+ and Mg2+ solution for total cell
counts using a manual haemocytometer. The differential cell
count was performed on cytospins stained with Diff-Quick by
counting 500 cells under a light microscope.
Biochemical assays
Albumin was measured by rocket electrophoresis as pre-
viously described.9 Histamine was measured by RIA
(Immunotech, Marseille, France) with a sensitivity of
0.02 ng/ml. Tryptase was measured by an immunoassay
(UniCAP, Pharmacia, Uppsala, Sweden) with a sensitivity of
1 ng/ml.
Statistical analyses
Changes in FEV1 during sputum induction were expressed as
mean (SE), and sputum cell counts and biochemical markers
as median (range). Assessment of the significance of a
bronchoconstriction during the sputum induction for each
procedure was performed using a one sample Student’s t test.
Comparisons of the maximal falls in FEV1 between the two
procedures were performed by a paired Student’s t test.
Comparisons of sputum cell counts and biochemical markers
between the two procedures were performed by the Wilcoxon
rank sum test, whereas reproducibility was assessed by calcu-
lating the intraclass coefficient of correlation as previously
Table 2 Treatment characteristics of study subjects
Visit A (n = 20)* Visit B (n = 20)*
Short acting b2 agonists
(puffs/week)
16 (0–70) 14 (0–64)










No controller medication (n) 3 3
*Visit A: premedication with inhaled salbutamol 400 mg pMDI; visit B:
premedication with inhaled salbutamol 400 mg pMDI + nebulised
salbutamol 1500 mg.
Table 1 Demographic and functional characteristics of study subjects
Visit A (n = 20) Visit B (n = 20)
Age (years)* 44 (23–82) 44 (23–82)
Sex (F/M) 11/9 11/9
Smoking habit 6/20 6/20
Pre-bronchodilator FEV1 (ml)* 2337 (1030–3670) 2306 (1120–3610)
Pre-bronchodilator FEV1 (% pred)* 73 (38–132) 73 (44–136)
Post-bronchodilator FEV1 (ml)* 2554 (1130–3500) 2651 (1170–3680)
Reversibility (%)* 13 (215–59) 17 (22–70)
Post-bronchodilator FEV1 (% pred)* 80 (40–143) 82 (40–142)
Post-bronchodilator FEV1 >65% 14/20 16/20
Post-bronchodilator FEV1 ,65% 6/20 4/20
*Age and lung function results are expressed as mean (range).
Visit A: premedication with inhaled salbutamol 400 mg pMDI. Visit B: premedication with inhaled salbutamol
400 mg pMDI + nebulised salbutamol 1500 mg.
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described.10 p values of ,0.05 were considered statistically
significant. Given the repeatability of the functional and
biochemical parameters and setting a risk error a at 0.05, our
sample size had a power of 98%, 96%, 82%, and 84% to detect
a 50% inhibition in the fall in FEV1 and of the sputum levels
of albumin, histamine and tryptase, respectively.
RESULTS
There was no significant difference between post-broncho-
dilator FEV1 values measured before starting sputum induc-
tion on visits A and B (table 1). All the subjects inhaled saline
for 10 minutes on both occasions. Sputum induction caused
significant bronchospasm that peaked at 10 minutes and
reached 10.4 (3.2)% (p,0.01) when subjects were premedi-
cated with 400 mg salbutamol inhaled through a pMDI and
spacer (visit A). In contrast, inhalation of the same amount
of saline did not produce any significant fall in FEV1 when
the patients received nebulised salbutamol in addition to
conventional premedication (visit B, fig 1). The maximal fall
in FEV1 over the 10 minute period was 11.7 (2.8)% at visit A
and 2.6 (1.2)% at visit B (fig 2). The mean (95% CI)
difference for the maximal fall in FEV1 between visits A and
B was 9% (2.7 to 15.4), p,0.01. Six of the 20 patients had a
fall in FEV1 of .20% at 10 minutes when premedicated with
the conventional procedure while none reached this thresh-
old when receiving nebulised salbutamol.
At visit A the mean maximal fall in FEV1 was 11.1 (3.6)%
(p,0.05, one sample t test) in patients who inhaled
hypertonic saline and 13.2 (4.9)% (p,0.05) in patients who
inhaled isotonic saline (post-bronchodilator FEV1 ,65%
predicted). The magnitude of the falls in FEV1 with the
conventional procedure was inversely related to baseline
FEV1 (r =20.46, p,0.05) and directly related to both the
extent of bronchodilation after inhaled salbutamol 400 mg
(r = 0.58, p,0.01) and the consumption of b2 agonist in the
preceding week (r = 0.44, p = 0.05).
At visit A, patients who were regularly treated with long
acting b2 agonists (n = 11) had a fall in FEV1 of 11.2 (3.8)%
compared with 12.5 (4.5)% in those not treated with long
acting b2 agonists (n = 9). When receiving nebulised salbu-
tamol, the fall in FEV1 was 2.4 (1.7)% in patients on regular
treatment with long acting b2 agonists and only 3 (1.6)% in
patients not so treated (fig 3).
Mean (SE) FEV1 values measured 10 and 20 minutes after
the end of sputum induction at visit A were 7.1 (1.9)% and
4.3 (2.4)%, respectively. Two subjects still had a fall in FEV1
of more than 20% by this time which was quickly reversed to
less than 5% of baseline by nebulised salbutamol (2500 mg)
and ipratropium bromide (250 mg). At visit B there was no
late bronchoconstriction following sputum induction since
mean FEV1 values remained above 95% of baseline at 10 and
20 minutes.
Although 18 patients produced an adequate sputum
sample on at least one occasion, only 15 produced readable
samples on both occasions allowing for comparison between
the two procedures. Sputum induction failed in two patients
at visit A and in two others at visit B. One patient was unable
to produce any sample at any visit. In the patients who
produced two adequate samples there was no significant
difference between sputum cell counts and sputum albumin,
tryptase and histamine levels measured at either visit
(table 3).
DISCUSSION
This study shows that the addition of salbutamol 1500 mg in
the ultrasonic nebuliser during sputum induction reinforces
the bronchoprotection obtained with 400 mg inhaled salbu-
tamol through pMDI in patients with moderate to severe
asthma. Improved bronchoprotection is observed irrespective
of current treatment with long acting b2 agonists. In addition,
inhalation of a high dose of salbutamol does not modify
cellular and mediator activity in the airway inflammatory
process as evidenced by sputum cell counts, and albumin,
tryptase and histamine levels.
Our data confirm that inhaling hypertonic and even
isotonic saline carries the risk of significant bronchospasm
in moderate to severe asthmatics despite premedication with
salbutamol 400 mg delivered by pMDI, which highlights the
need to improve the safety of the procedure. We have shown




















NaCl + nebulised salbutamol
Figure 1 Time course of bronchoconstriction during sputum induction
by inhalation of hypertonic or isotonic saline in 20 patients with
























NaCl 0.9% + salbutamol
NaCl 5% + salbutamol
Visit A Visit B
Figure 2 Distribution of the maximal falls in forced expiratory volume






















Visit A Visit B Visit A Visit B
With LABA Without LABA
NaCl 0.9%
NaCl 5%
Figure 3 Comparison of the maximal falls in FEV1 between patients
treated and not treated with long acting b2 agonists (LABA).
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that complementary salbutamol (1500 mg) inhaled through
an ultrasonic nebuliser markedly reduces the intensity of
bronchospasm seen in patients with moderate to severe
asthma undergoing sputum induction. None of the 20
patients studied had a fall in FEV1 of more than 20% during
sputum induction when receiving nebulised salbutamol
compared with six patients who had a fall in FEV1 of more
than 20% (range 20.3–37.2%) at the end of sputum induction
when only receiving 400 mg inhaled salbutamol through
pMDI. In our study the rate of significant bronchospasm
(30%) with standard premedication is slightly higher than
that reported by Fahy et al (14%) in a recent multicentre
study of asthmatics whose baseline FEV1 values were very
similar to those of our subjects.11
In agreement with previous studies,12 13 we found that both
baseline FEV1 values and b2 agonist consumption are
parameters that may influence the magnitude of broncho-
spasm following inhalation of saline. It is therefore worth
noting that these two parameters were similar between visits
A and B, making comparison between the two study days
valid. The relationship between the dose of inhaled salbuta-
mol and the extent of bronchoprotection has only been
studied over a narrow range of concentrations so far. Bel and
colleagues14 showed that salbutamol 200 and 400 mg inhaled
through a pMDI were both very efficient in shifting to the
right the concentration of histamine or methacholine
provoking a fall in FEV1 of 20% or more (PC20) with a small
dose related effect for PC20 histamine but not for PC20
methacholine.14 Inhalation of salbutamol 100–400 mg by MDI
produces strong bronchoprotection against methacholine
that is, however, weakly proportional to the dose since 80%
of protection is already achieved with 100 mg.15 On the other
hand, inhalation of 1600 mg salbutamol dry powder on top of
regular treatment with salmeterol (50 mg twice daily) or
formoterol (12 mg twice daily) did not increase the broncho-
protection towards methacholine. The inability of a dose of
salbutamol similar to the one we used and administered
through a dry powder inhaler to further improve the
bronchoprotection given by long acting b2 agonists
16 therefore
suggests that, in our study, the ultrasonic nebulisation itself
may well reinforce the bronchoprotection obtained with
salbutamol.
By showing no difference in the magnitude of broncho-
spasm induced by saline inhalation between patients with
and without long acting b2 agonists, our results indicate that
it would be unwise to consider that asthmatic patients are
always protected against saline induced bronchoconstriction
when regularly treated with long acting b2 agonists. The
tolerance in bronchoprotection produced by chronic usage of
b2 agonists may be involved.
17 However, it should be kept in
mind that the patients in our study who received long acting
b2 agonists also suffered from more severe asthma, exhibiting
the poorest baseline lung function, and were therefore the
most likely to show a dramatic change in FEV1 after saline.
It is interesting that the delivery of high dose salbutamol
into the airways does not alter the profile of sputum cells nor
its albumin, tryptase and histamine content. Inhalation of
hypertonic saline may trigger mast cell degranulation18 and
favour vascular leakage19 into the airways. On the other hand,
there is evidence in the literature that b2 agonists can prevent
mast cell degranulation and inhibit plasma exudation.7 As
these two properties may theoretically partly contribute to
the bronchoprotective effect of b2 agonists,
20 we wished to
determine whether inhalation of a high dose of salbutamol,
compared with a low dose, has any effect on the sputum
content of mast cell derived mediators and a marker of
plasma exudation. Our results show that high dose salbuta-
mol had no effect on the levels of histamine, tryptase, or
albumin. This suggests that the greater bronchoprotective
effect of high dose salbutamol is neither related to mast cell
stabilisation nor to the anti-exudative effect during sputum
induction.
This study shows that additional inhalation of salbutamol
through an ultrasonic nebuliser improves the safety of
sputum induction in patients with moderate to severe asthma
without altering its cellular and biochemical content. We
believe that this may be of practical importance to the
investigation of airways inflammation in patients with
moderate to severe asthma.
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Higher tuberculosis mortality in India seen in those who have ever smoked
m Gajalakshmi V, Peto R, Santhanakrishna T, Jha P. Smoking and mortality from tuberculosis and other diseases in India:
retrospective study of 43 000 adult male deaths and 35 000 controls. Lancet 2003;362:507–15.
T
his case-control study examined the smoking habits and medical causes of mortality in
men from southern India. The death rates of current or former smokers were double
those of never smokers (RR = 2.1 (95% CI 2.0 to 2.2)). Of this excess mortality among
smokers, a third involved respiratory disease. Tuberculosis was the chief cause of respiratory
mortality (4.5 (95% CI 4.0 to 5.0), smoking attributed fraction 61%). A separate survey of
250 000 men living in the urban study area found that smokers are three times more likely
than never smokers to report a history of tuberculosis, corresponding to a higher rate of
progression of chronic subclinical infection to clinical disease. The authors conclude that
smoking, which is a cause of half the deaths from tuberculosis in men in India, increases the
incidence of clinical tuberculosis.
This and similar studies will no doubt stimulate research into the mechanisms behind
reactivation of tuberculosis by smoking. Some clues may be derived from the reported
effects of smoking on other diseases. Smokers have a reduced incidence of sarcoidosis and
extrinsic allergic alveolitis, diseases in which tumour necrosis factor-a (TNF-a) plays a key
role. Moreover, the use of anti-TNF-a agents for conditions such as rheumatoid arthritis
leads to reactivation of tuberculosis. Collectively, these data converge on the hypothesis that
smoking might oppose the release or function of TNF-a in the lungs. Recent work on the
effects of nicotine has revealed likely pathways (Wang H, et al. Nature 2003;421:384–8;
Borovikova LV, et al. Nature 2000;405:458–62).
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